Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Newman Dignan & Sheerar Inc.

Newman Dignan & Sheerar Inc. lifted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 786 shares of the pharmaceutical company’s stock after acquiring an additional 25 shares during the quarter. Newman Dignan & Sheerar Inc.’s holdings in Vertex Pharmaceuticals were worth $350,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in VRTX. Activest Wealth Management purchased a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at $25,000. Clal Insurance Enterprises Holdings Ltd increased its stake in Vertex Pharmaceuticals by 450.0% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 45 shares during the period. Flaharty Asset Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the first quarter worth about $32,000. American National Bank & Trust grew its holdings in shares of Vertex Pharmaceuticals by 515.4% in the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock valued at $36,000 after purchasing an additional 67 shares in the last quarter. Finally, SJS Investment Consulting Inc. boosted its position in Vertex Pharmaceuticals by 46.2% in the 1st quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company’s stock valued at $46,000 after buying an additional 30 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Guggenheim dropped their price target on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. BMO Capital Markets set a $530.00 target price on Vertex Pharmaceuticals and gave the stock an “outperform” rating in a research note on Tuesday, August 5th. JPMorgan Chase & Co. increased their price target on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an “overweight” rating in a research report on Monday, July 14th. Truist Financial set a $490.00 price objective on Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 5th. Finally, UBS Group set a $553.00 target price on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eleven have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $493.81.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $404.21 on Thursday. The stock’s 50-day moving average is $401.71 and its two-hundred day moving average is $444.45. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.88. The firm has a market cap of $103.64 billion, a price-to-earnings ratio of 28.89 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. The firm had revenue of $2.94 billion during the quarter, compared to analysts’ expectations of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business’s revenue was up 11.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were acquired at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the transaction, the director owned 45,000 shares in the company, valued at approximately $17,535,600. The trade was a 12.50% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.